What is the appropriate work‑up and management for a patient with a reactive hepatitis B surface antigen (HBsAg) and negative hepatitis B surface antibody (anti‑HBs)?

Management of Reactive HBsAg with Negative Anti-HBs

A patient with reactive (positive) HBsAg and negative anti-HBs has chronic hepatitis B infection and requires immediate additional serologic testing, baseline assessment of disease activity, and consideration for antiviral therapy based on HBV DNA levels, ALT, and degree of liver fibrosis. 1

Initial Work-Up

Complete the Serologic Panel

• Obtain hepatitis B e antigen (HBeAg) and anti-HBe antibody to determine if the patient has HBeAg-positive or HBeAg-negative chronic hepatitis B 1
• Check anti-HBc (total IgG or IgG) to confirm chronic infection (should be positive) 1
• The absence of anti-HBs with positive HBsAg confirms active infection rather than resolved infection 1

Baseline Disease Assessment

• Measure HBV DNA level (quantitative PCR) to assess viral replication 1
• Check ALT (alanine aminotransferase) to evaluate hepatic inflammation 1
• Assess liver fibrosis using non-invasive methods (transient elastography/FibroScan) or liver biopsy if indicated 1
• Screen for hepatocellular carcinoma (HCC) with abdominal ultrasound and AFP, especially if cirrhosis is present 1

Risk Stratification and Treatment Decisions

Patients with HBV DNA ≥2000 IU/mL and Elevated ALT

These patients should initiate antiviral therapy immediately with entecavir or tenofovir (TDF/TAF), as they have active chronic hepatitis B with significant risk of progression to cirrhosis and HCC 1

Patients with HBV DNA ≥2000 IU/mL and Normal ALT

• Perform liver biopsy or transient elastography to assess histologic disease 1
• If significant fibrosis (≥F2) or inflammation is detected, initiate antiviral therapy 1
• If no significant histologic disease, monitor ALT every 3 months and HBV DNA every 6 months for rises indicating need for treatment 1

Patients with Cirrhosis (Compensated or Decompensated)

All patients with cirrhosis and detectable HBV DNA should receive immediate antiviral therapy regardless of ALT level, as they are at highest risk for decompensation and HCC 1

Preferred Antiviral Agents

First-line therapy is entecavir (0.5 mg daily) or tenofovir (TDF 300 mg or TAF 25 mg daily), both of which have high potency, high barriers to resistance, and excellent safety profiles 1

• These agents achieve >90% virologic suppression after 3 years in treatment-adherent patients 1
• Long-term therapy can lead to regression of fibrosis and even reversal of cirrhosis 1
• Peginterferon alfa-2a is an alternative for 48 weeks in non-cirrhotic patients, offering finite therapy with higher rates of HBsAg loss, but has significant side effects and requires subcutaneous injection 1

Special Considerations

Absence of Anti-HBs Increases Reactivation Risk

Patients negative for anti-HBs are at higher risk of HBV reactivation during immunosuppressive therapy compared to those with positive anti-HBs 1

• If the patient will undergo chemotherapy, immunosuppression, or anti-CD20 therapy (rituximab), prophylactic antiviral therapy is mandatory regardless of baseline HBV DNA 1
• Antiviral prophylaxis should continue during therapy and for at least 12 months after cessation (18 months for rituximab-based regimens) 1

Monitoring During Therapy

• Check HBV DNA and ALT every 6 months during antiviral therapy 1
• Monitor for HCC with ultrasound every 6 months in all cirrhotic patients and high-risk non-cirrhotic patients 1
• After antiviral discontinuation (if applicable), monitor ALT monthly for 3 months, then every 3 months, as hepatitis flares can occur 1

Duration of Therapy

• Lifelong therapy is recommended for patients with decompensated cirrhosis or compensated cirrhosis (F4) at treatment initiation 1
• For HBeAg-positive patients without advanced fibrosis, therapy may be discontinued after HBeAg seroconversion with consolidation therapy, though optimal duration remains unclear 1
• HBsAg loss for 6-12 months is the ideal endpoint allowing treatment discontinuation in non-cirrhotic patients, though lifelong HCC surveillance remains necessary if cirrhosis was ever present 1

Coordination of Care

Referral to or coordination with a hepatologist or clinician experienced in HBV management is strongly recommended, particularly for determining long-term monitoring strategies, evaluating for advanced liver disease, and managing treatment discontinuation 1